Multitarget selection of catalytic antibodies with β‐lactamase activity using phage display
Melody A. Shahsavariana b, Nancy Chaayaa b, Narciso Costac, Didier Boquetc, Alexandre P. Atkinsond, Bernard Offmannd, Srini V. Kaverib e f g h, Sébastien Lacroix‐Desmazesb e f g h, Alain Fribouleta b, Bérangère Avallea b, Séverine Padiolleau‐Lefèvrea b✉
- aGénie Enzymatique et Cellulaire (GEC) FRE 3580 CNRS Université de Technologie de Compiègne France
- bUMR S 1138 Sorbonne Universités Université Pierre et Marie Curie – Paris VI France
- cService de Pharmacologie et d'Immuno‐analyse (SPI) IBITECS, CEA Université Paris‐Saclay Gif‐sur‐Yvette France
- dUnité Fonctionnalité et Ingénierie des Protéines (UFIP) UMR CNRS 6286 Université de Nantes France
- eEquipe Immunopathology and Therapeutic Immunointervention Centre de Recherche des Cordeliers Paris France
- fInstitut National de la Santé et de la Recherche Médicale (INSERM) U 1138 Paris France
- gInternational Associated Laboratory IMPACT Institut National de la Santé et de la Recherche Médicale‐France and Indian Council of Medical Research‐India National Institute of Immunohaemotology Mumbai India
- hEquipe Immunopathology and Therapeutic Immunointervention, Centre de Recherche des Cordeliers, Paris, France
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
β‐lactamase enzymes responsible for bacterial resistance to antibiotics are among the most important health threats to the human population today. Understanding the increasingly vast structural motifs responsible for the catalytic mechanism of β‐lactamases will help improve the future design of new generation antibiotics and mechanism‐based inhibitors of these enzymes. Here we report the construction of a large murine single chain fragment variable (scFv) phage display library of size 2.7 × 109 with extended diversity by combining different mouse models. We have used two molecularly different inhibitors of the R‐TEM β‐lactamase as targets for selection of catalytic antibodies with β‐lactamase activity. This novel methodology has led to the isolation of five antibody fragments, which are all capable of hydrolyzing the β‐lactam ring. Structural modeling of the selected scFv has revealed the presence of different motifs in each of the antibody fragments potentially responsible for their catalytic activity. Our results confirm (a) the validity of using our two target inhibitors for the in vitro selection of catalytic antibodies endowed with β‐lactamase activity, and (b) the plasticity of the β‐lactamase active site responsible for the wide resistance of these enzymes to clinically available inhibitors and antibiotics.
TL;DRThe construction of a large murine single chain fragment variable (scFv) phage display library of size 2.7 × 109 with extended diversity by combining different mouse models is reported, confirming the validity of using two target inhibitors for the in vitro selection of catalytic antibodies endowed with β‐lactamase activity. (Semantic Scholar)